Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
13 juil. 2022 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Arthritis Foundation Adds Arthritis Challenge Experience to the 2022 California Coast Classic Bicycle Tour, Presented by Amgen
28 avr. 2022 09h00 HE
|
The Arthritis Foundation’s California Coast Classic Bicycle Tour
LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Organizers of the 2022 California Coast Classic Bicycle Tour + Arthritis Challenge Experience presented by Amgen, today announced that 70 spaces...
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
10 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
FIVE PRIME ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FPRX and Encourages Investors to Contact the Firm
04 mars 2021 12h02 HE
|
Bragar Eagel & Squire
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510
09 juin 2020 07h30 HE
|
Revolution Medicines, Inc.
Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) --...
Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen
09 sept. 2019 07h00 HE
|
Toronto Innovation Acceleration Partners
Toronto, Ontario, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Toronto Innovation Acceleration Partners (TIAP – formerly MaRS Innovation), a leading member-based Canadian provider of venture builder expertise...
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
17 avr. 2019 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Innovest Global Provides Acquisition Update: Authority National Supply Closing Rescheduled to First Week of November and Secured LOI for $12 Million Revenue and Profitable Acquisition in the Building Industry
26 oct. 2018 09h28 HE
|
Innovest Global, Inc
CLEVELAND, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a conglomerate with operations in commercial and industrial products and...
Innovest Global: Record Sales, Major Clients, Significant Growth Mark 1st Half 2018 Letter to Shareholders, Q2 Report
23 juil. 2018 07h50 HE
|
Innovest Global, Inc
CLEVELAND, July 23, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Pink Current:IVST) (the “Company” or “Innovest”), posted Q2 financial reports this morning, and the following Shareholder...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
13 déc. 2017 13h13 HE
|
Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...